Skip to content
Head to head

Intellia Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: NTLA · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

NTLA +17.9%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals earns the most per share.
NTLAVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price10.00515.02
Change today+5.04%-1.08%
1-year return+24.4%+22.0%
Market cap$1.40B$130.58B
52-week range8.09 – 18.48412.27 – 568.67
Valuation
P/E (TTM)-2.9933.14
P/E percentile, own 5-yr range78th99th
P/B2.296.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.8115.32
Net profit (TTM)$-534.77M$3.88B
Revenue (TTM)$52.89M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-48.0%+11.8%
Gross margin--85.5%
Operating margin-821.2%33.1%
Net margin-805.7%30.7%
Free cash flow (TTM)$-358.08M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership103.7%96.8%
Insider activity (12mo)31 buy / 19 sell28 buy / 22 sell
Short interest (% of float)31.7%1.9%
Analyst consensus36% buy / 45% hold / 18% sell (11)95% buy / 5% hold (21)
Analyst price target$19 (+92%)$624 (+21%)
StockVane view
StockVane Quant RatingD (66)C (68)
Company
Employees3776,400
Founded20141989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.